基于KEYNOTE-042研究PD-L1≥1%的NSCLC患者使用帕博利珠单抗或化疗作为一线治疗的5年结局

First-Line Pembrolizumab Versus Chemotherapy in PD-L1 Positive Non-Small-Cell Lung Cancer:5-Year Outcomes From the KEYNOTE-042 Study

1文献来源de Castro G Jr,Kudaba I,Wu YL,et al. Fiveyear outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with nonsmall-cell lung cancer and programmed death ligand-1tumor proportion score≥1%in the KEYNOTE-042 study[J]. J Clin Oncol,2023,41(11):1986-1991.2证据水平1b。